Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. Issue 9 (22nd September 2022)

• Record Type: Journal Article
• Authors: Gupta, Shruti; Garcia-Carro, Clara; Prosek, Jason M; Glezerman, Ilya; Herrmann, Sandra M; Garcia, Pablo; Abudayyeh, Ala; Lumlertgul, Nuttha; Malik, A Bilal; Loew, Sebastian; Beckerman, Pazit; Renaghan, Amanda D; Carlos, Christopher A; Rashidi, Arash; Mithani, Zain; Deshpande, Priya; Rangarajan, Sunil; Shah, Chintan V; Seigneux, Sophie De; Campedel, Luca; Kitchlu, Abhijat; Shin, Daniel Sanghoon; Coppock, Gaia; Ortiz-Melo, David I; Sprangers, Ben; Aggarwal, Vikram; Benesova, Karolina; Wanchoo, Rimda; Murakami, Naoka; Cortazar, Frank B; Reynolds, Kerry L; Sise, Meghan E; Soler, Maria Jose; Leaf, David E;
• Other Names: author non-byline.; Campedel Luca author non-byline.; Salem Joe-Elie author non-byline.; Bagnis Corinne Isnard author non-byline.; Gupta Shruti author non-byline.; Leaf David E author non-byline.; Singh Harkarandeep author non-byline.; Motwani Shveta S author non-byline.; Murakami Naoka author non-byline.; Tio Maria C author non-byline.; Mothi Suraj S author non-byline.; Selamet Umut author non-byline.; Loew Sebastian author non-byline.; Schmidt-Ott Kai M author non-byline.; Chang Weiting author non-byline.; Jhaveri Kenar D author non-byline.; Wanchoo Rimda author non-byline.; Khanin Yuriy author non-byline.; Hirsch Jamie S author non-byline.; Sakhiya Vipulbhai author non-byline.; Stalbow Daniel author non-byline.; Wu Sylvia author non-byline.; Ortiz-Melo David I author non-byline.; Ostermann Marlies author non-byline.; Lumlertgul Nuttha author non-byline.; Seylanova Nina author non-byline.; Cennamo Armando author non-byline.; Rigg Anne author non-byline.; Shaunak Nisha author non-byline.; Kibbelaar Zoe A author non-byline.; Benesova Karolina author non-byline.; Deshpande Priya author non-byline.; Sise Meghan E author non-byline.; Reynolds Kerry L author non-byline.; Seethapathy Harish S author non-byline.; Lee Meghan author non-byline.; Strohbhen Ian A author non-byline.; Herrmann Sandra M author non-byline.; Isik Busra author non-byline.; Glezerman Ilya G author non-byline.; Cortazar Frank B author non-byline.; Aggarwal Vikram author non-byline.; Chandra Sunandana author non-byline.; Prosek Jason M author non-byline.; Madhavan Sethu M. author non-byline.; Owen Dwight H author non-byline.; Husain Marium author non-byline.; Beckerman Pazit author non-byline.; Mini Sharon author non-byline.; Anand Shuchi author non-byline.; Garcia Pablo author non-byline.; Kaghazchi Aydin author non-byline.; Rangarajan Sunil author non-byline.; Shin Daniel Sanghoon author non-byline.; Cherry Grace author non-byline.; Carlos Christopher A author non-byline.; Hsu Raymond K author non-byline.; Kisel Andrey author non-byline.; Rashidi Arash author non-byline.; Kansal Sheru K author non-byline.; Albert Nicole author non-byline.; Carter Katherine author non-byline.; Donley Vicki author non-byline.; Young Tricia author non-byline.; Cigoi Heather author non-byline.; Seigneux Sophie De author non-byline.; Koessler Thibaud author non-byline.; Ben Sprangers Els Wauters author non-byline.; Shah Chintan V author non-byline.; Eijgelsheim Mark author non-byline.; Mithani Zain author non-byline.; Pagan Javier A author non-byline.; Coppock Gaia author non-byline.; Hogan Jonathan J author non-byline.; Abudayyeh Ala author non-byline.; Mamlouk Omar author non-byline.; Lin Jamie S author non-byline.; Page Valda author non-byline.; Kitchlu Abhijat author non-byline.; Short Samuel AP author non-byline.; Renaghan Amanda D author non-byline.; Gaughan Elizabeth M author non-byline.; Bilal Malik A author non-byline.; Soler Maria Jose author non-byline.; García-Carro Clara author non-byline.; Bermejo Sheila author non-byline.; Felip Enriqueta author non-byline.; Muñoz-Couselo Eva author non-byline.; Carreras Maria Josep author non-byline.;
• Is Part Of: Journal for immunotherapy of cancer. Volume 10:Issue 9(2022)
• Publication Date: 2022-09-22
• Subjects: Immunotherapy; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2022-005646
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free survival among patients treated with ICPis. We sought to determine whether a shorter duration of corticosteroids was equally efficacious and safe as compared with a longer duration. Methods: We used data from an international multicenter cohort study of patients diagnosed with ICPi-AKI from 29 centers across nine countries. We examined whether a shorter duration of corticosteroids (28 days or less) was associated with a higher rate of recurrent ICPi-AKI or death within 30 days following completion of corticosteroid treatment as compared with a longer duration (29–84 days). Results: Of 165 patients treated with corticosteroids, 56 (34%) received a shorter duration of treatment and 109 (66%) received a longer duration. Patients in the shorter versus longer duration groups were similar with respect to baseline and ICPi-AKI characteristics. Five of 56 patients (8.9%) in the shorter duration group and 12 of 109 (11%) in the longer duration group developed recurrent ICPi-AKI or died (p=0.90). Nadir serum creatinine in the first 14, 28, and 90 days following completion of corticosteroid treatment was similar between groups (p=0.40, p=0.56, and p=0.89, respectively). Conclusion: A shorter duration of corticosteroids (28 days or less) may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.